↓ Skip to main content

Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial

Overview of attention for article published in Trials, March 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter
13 X users
facebook
1 Facebook page

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
141 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase iii trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial
Published in
Trials, March 2015
DOI 10.1186/s13063-015-0602-8
Pubmed ID
Authors

Sarah R Kingsbury, Puvan Tharmanathan, Nigel K Arden, Michael Batley, Fraser Birrell, Kim Cocks, Michael Doherty, Chris J Edwards, Toby Garrood, Andrew J Grainger, Michael Green, Catherine Hewitt, Rod Hughes, Robert Moots, Terence W O’Neill, Edward Roddy, David L Scott, Fiona E Watt, David J Torgerson, Philip G Conaghan

Abstract

Osteoarthritis (OA) is the fastest growing cause of disability worldwide. Current treatments for OA are severely limited and a large proportion of people with OA live in constant, debilitating pain. There is therefore an urgent need for novel treatments to reduce pain. Synovitis is highly prevalent in OA and is associated with pain. In inflammatory arthritides such as rheumatoid arthritis, methotrexate (MTX) is the gold standard treatment for synovitis and has a well-known, acceptable toxicity profile. We propose that using MTX to treat patients with symptomatic knee OA will be a practical and safe treatment to reduce synovitis and, consequently, pain. Pain Reduction with Oral Methotrexate in knee Osteoarthritis, a pragmatic phase III trial of Treatment Effectiveness (PROMOTE) is an investigator-initiated, multi-centre, randomized, double-blind, pragmatic placebo-controlled trial. A total of 160 participants with symptomatic knee OA will be recruited across primary and secondary care sites in the United Kingdom and randomized on a 1:1 basis to active treatment or placebo, in addition to usual care, for 12 months. As is usual practice for MTX, dosing will be escalated over six weeks to 25 mg (or maximum tolerated dose) weekly for the remainder of the study. The primary endpoint is change in average knee pain during the past week (measured on an 11-point numerical rating scale) between baseline and six months. Secondary endpoints include other self-reported pain, function and quality-of-life measures. A health economics analysis will also be performed. A magnetic resonance imaging substudy will be conducted to provide an explanatory mechanism for associated symptom change by examining whether MTX reduces synovitis and whether this is related to symptom change. Linear and logistic regression will be used to compare changes between groups using univariable and multivariable modelling analyses. All analyses will be conducted on an intention-to-treat basis. The PROMOTE trial is designed to examine whether MTX is an effective analgesic treatment for OA. The MRI substudy will address the relationship between synovitis and symptom change. This will potentially provide a much needed new treatment for knee OA. Current Controlled Trials identifier: ISRCTN77854383 (registered: 25 October 2013).

X Demographics

X Demographics

The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 141 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 141 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 12%
Student > Master 16 11%
Student > Ph. D. Student 14 10%
Student > Postgraduate 12 9%
Student > Bachelor 12 9%
Other 30 21%
Unknown 40 28%
Readers by discipline Count As %
Medicine and Dentistry 49 35%
Nursing and Health Professions 13 9%
Biochemistry, Genetics and Molecular Biology 6 4%
Pharmacology, Toxicology and Pharmaceutical Science 6 4%
Agricultural and Biological Sciences 3 2%
Other 17 12%
Unknown 47 33%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2021.
All research outputs
#3,879,445
of 23,310,485 outputs
Outputs from Trials
#1,462
of 6,024 outputs
Outputs of similar age
#47,656
of 258,833 outputs
Outputs of similar age from Trials
#20
of 127 outputs
Altmetric has tracked 23,310,485 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,024 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.3. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 258,833 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 127 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.